Juniper Pharmaceuticals (JNP) Lowered to “Sell” at ValuEngine
Juniper Pharmaceuticals (NASDAQ:JNP) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Juniper Pharmaceuticals in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Juniper Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $23.00.
Shares of Juniper Pharmaceuticals (NASDAQ JNP) opened at $5.03 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.00. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $6.10. The company has a market capitalization of $54.49, a P/E ratio of 7.85 and a beta of 0.03.
COPYRIGHT VIOLATION WARNING: “Juniper Pharmaceuticals (JNP) Lowered to “Sell” at ValuEngine” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/03/juniper-pharmaceuticals-jnp-lowered-to-sell-at-valuengine.html.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.